PepScribe

Guide · Dosing

Tirzepatide calculator: what you actually need to know. - Reddit

Last updated July 1, 2026

More: Clinical standards · Pharmacy partners

People searching for a tirzepatide calculator usually have a concrete question: how many units do I draw, or how do I convert mg to mL for my specific vial? This guide answers those questions — and explains why no online calculator should replace the instructions your prescribing clinician and pharmacy provide.

Quick answer

Tirzepatide is measured in milligrams (mg), not “units” — the unit system is for insulin, not for GLP-1/GIP peptides. To find your syringe draw volume, divide your prescribed mg dose by your vial’s concentration in mg/mL; for example, a 2.5 mg dose from a 5 mg/mL vial = 0.5 mL. Because 503A compounding pharmacies prepare tirzepatide at varying concentrations, your pharmacy label and clinician’s written instructions are the only reliable inputs — no generic online calculator can substitute for them.

Key takeaways

  • Tirzepatide is dosed in milligrams, not “units” — the unit system is for insulin, and applying it here produces a dangerously wrong volume.
  • Draw volume = dose (mg) ÷ concentration (mg/mL); e.g., a 2.5 mg dose from a 5 mg/mL vial is 0.5 mL.
  • 503A pharmacies compound tirzepatide at varying concentrations, so the same mg dose can mean different volumes — your vial label is the only reliable input.
  • The standard trial titration is 2.5 → 5 → 10 → 15 mg in four-week steps; many patients hold at 5 mg or 10 mg rather than reaching ceiling.
  • If a compounded vial arrives without a labeled concentration and patient-specific instructions, contact the clinician or pharmacy before drawing.

A licensed clinician prescribes your dose and the pharmacy labels the concentration, so your draw volume is never a guess.

Take the free assessment

Tirzepatide is dosed in milligrams — not units

The most important clarification upfront: tirzepatide is measured in milligrams (mg), not “units.” The term “units” is a dosing standard used for insulin — where 1 unit corresponds to a defined biological activity. Tirzepatide does not use that system.

When people search for a tirzepatide unit converter or mg-to-units calculation, they are usually conflating tirzepatide with insulin dosing conventions. This confusion matters because if you apply an insulin-unit conversion to a tirzepatide vial, you will calculate a completely wrong volume and could significantly over- or under-dose yourself.

Your tirzepatide dose is in mg. The syringe volume you draw depends on the concentration of your specific vial.

How does concentration determine my draw volume?

The relationship between your prescribed dose (mg) and what you draw in a syringe (mL) is straightforward — once you know the concentration of your vial:

Volume (mL) = Dose (mg) ÷ Concentration (mg/mL)

For example: if your vial is 5 mg/mL and your prescribed dose is 2.5 mg, you draw 0.5 mL. If your vial is 10 mg/mL and your dose is 2.5 mg, you draw 0.25 mL. The same dose, two different draw volumes — because concentration differs.

This is exactly why the concentration printed on your vial and the instructions from your pharmacy are the only inputs that matter. There is no single standard concentration for compounded tirzepatide — 503A pharmacies can prepare it at various concentrations, and what you receive depends on the specific formulation your clinician prescribed.

There is no universal mg-to-units conversion for tirzepatide — the concentration printed on your specific vial is the only number that matters.

What the clinical dose escalation schedule looks like

In the SURMOUNT clinical trials, the standard tirzepatide escalation for weight management was:

  • 2.5 mg/week for the first 4 weeks (initiation)
  • 5 mg/week for weeks 5–8
  • 10 mg/week for weeks 9–12
  • 15 mg/week as the maintenance target from week 13 onward

This is the trial protocol, not a mandatory schedule. Clinicians regularly modify escalation based on individual tolerability. Many patients stay at 5 mg or 10 mg rather than escalating to 15 mg — either because they’ve met their goals, or because they can’t tolerate higher doses. The ceiling is not the target for everyone.

Why aren’t online calculators safe for injectable drugs like tirzepatide?

Search engines return calculator tools that claim to convert tirzepatide mg to draw volume. The problem: these tools require you to input a concentration, and if you input the wrong concentration — or use a generic assumption — the calculation is wrong in a way that could cause real harm.

Injectable GLP-1 agents are not over-the-counter products. The dose your clinician prescribes is based on your weight, history, and goals. The draw volume is specific to the vial your pharmacy prepares. A calculator that doesn’t have your specific vial’s concentration verified cannot give you a reliable number.

If you are unsure about your draw volume, the correct action is to contact your prescribing clinician or the dispensing pharmacy — not to calculate independently using generic conversion tables.

What compounded tirzepatide from a licensed 503A pharmacy looks like

Compounded tirzepatide prepared by a licensed 503A pharmacy in the United States arrives as:

  • A sterile, multi-dose vial with a rubber septum, refrigerated.
  • A label with the concentration in mg/mL, lot number, expiration date, and patient name.
  • Dosing instructions from the prescribing clinician specifying the mg dose per injection and, typically, the draw volume for that specific vial.

If you receive a compounded tirzepatide vial without a clearly labeled concentration and patient-specific instructions, that is a red flag — and a reason to contact the prescribing clinician or pharmacy immediately.

Compounded peptides obtained from non-pharmacy sources — research chemical vendors, gray-market suppliers, overseas distributors — carry real risks of incorrect concentration labeling, contamination, and incorrect identity. PepScribe’s pharmacy standard is 503A-only: compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.

Practical injection guidance

Once you have your vial and instructions from your prescribing clinician and pharmacy:

  • Syringe size:Use an appropriately sized syringe for the volume you’re drawing. For small volumes (0.1–0.5 mL), an insulin syringe (1 mL) is commonly used for precision.
  • Injection sites: Abdomen, upper thigh, and upper arm are standard subcutaneous sites. Rotate weekly to reduce injection-site reactions.
  • Storage:Refrigerate vials; do not freeze. Most compounded GLP-1 vials are stable refrigerated for the labeled period. Check your specific pharmacy’s guidance.
  • Injection day timing: Choose a consistent day of the week. Weekly injections work best when taken at approximately the same time each week to maintain stable drug levels.

Frequently asked questions

How do I convert tirzepatide mg to units?

There is no universal mg-to-unit conversion for tirzepatide because "units" is not a standardized term for this drug — it is used for insulin, not tirzepatide. Tirzepatide doses are measured in milligrams (mg). The volume you draw in a syringe depends on the concentration of the specific vial you are using, which is why your clinician and pharmacy provide clear instructions. Do not use online conversion tools for injectable medication dosing.

What concentration is compounded tirzepatide?

Compounded tirzepatide from licensed 503A pharmacies can be prepared at various concentrations. Your pharmacy will specify the concentration (e.g., mg/mL) on the vial. Your clinician prescribes the dose in mg; the pharmacy and instructions convert that to a draw volume for your specific vial. Never assume a generic concentration.

What is the standard tirzepatide dose escalation schedule?

In clinical trials (SURMOUNT), the standard escalation was: 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then 10 mg for 4 weeks, then 15 mg as the maintenance target. Clinicians may modify this based on individual tolerability. Some patients maintain at 5 mg or 10 mg rather than escalating to ceiling.

What does the tirzepatide vial look like for compounded versions?

Compounded tirzepatide comes as a sterile solution in a vial, typically with a rubber septum for subcutaneous injection with a fine needle. Reconstituted peptide vials from licensed 503A pharmacies should arrive refrigerated, labeled with concentration and expiration, and accompanied by instructions from the prescribing clinician.

Can I calculate my own tirzepatide dose?

No. Tirzepatide is a prescription medication and dose calculations for injectable drugs require knowing the exact concentration of your specific vial. Self-calculating without a clinician is unsafe and bypasses the oversight that compounded GLP-1 therapy requires. Your prescribed instructions will tell you what volume to draw.

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (Jastreboff et al.) — PMID 35658024 (2022).
  2. 503A Compounding — FDA Policy on Compounded Drugs. U.S. Food & Drug Administration — Human Drug Compounding (n.d.).
  3. Efficacy and tolerability of tirzepatide versus semaglutide (SURPASS-2). New England Journal of Medicine (Frías et al.) — PMC8496018 (2021).

Get tirzepatide with proper clinician dosing guidance.

3-minute assessment. Clinician-prescribed dose. Compounded in the USA by licensed 503A pharmacies — concentration labeled, instructions included. No hidden overseas supply chain.